Search results for "Furosemide"

showing 10 items of 73 documents

Dopaminergic-GABAergic interplay and alcohol binge drinking

2019

© 2019 Elsevier Ltd The dopamine D 3 receptor (D 3 R), in the nucleus accumbens (NAc), plays an important role in alcohol reward mechanisms. The major neuronal type within the NAc is the GABAergic medium spiny neuron (MSN), whose activity is regulated by dopaminergic inputs. We previously reported that genetic deletion or pharmacological blockade of D 3 R increases GABA A α6 subunit in the ventral striatum. Here we tested the hypothesis that D 3 R-dependent changes in GABA A α6 subunit in the NAc affect voluntary alcohol intake, by influencing the inhibitory transmission of MSNs. We performed in vivo and ex vivo experiments in D 3 R knockout (D 3 R −/− ) mice and wild type littermates (D 3 …

0301 basic medicineMalemedicine.medical_specialtyDopaminergic-GABAergicSettore BIO/09 - FISIOLOGIAAlpha6 subunit; Dopamine D3 receptor; Ethanol; Furosemide (PubChem CID: 3440); GABA(A)receptor; Nucleus accumbens; Ro 15-4513; Ro 15-4513 (PubChem CID: 5081); SB 277011A (PubChem CID: 75358288)Alpha6 subunitNucleus accumbensMedium spiny neuronInhibitory postsynaptic potentialNucleus AccumbensBinge Drinking03 medical and health sciencesMiceDopamine D3 receptor0302 clinical medicineDopamine receptor D3Internal medicinemedicineAnimalsFurosemide (PubChem CID: 3440)Nucleus accumbenPharmacology & PharmacyRNA MessengerRo 15-4513GABAergic NeuronsSB 277011A (PubChem CID: 75358288).PharmacologyMice KnockoutEthanolGABAA receptorChemistryDopaminergicAntagonistReceptors Dopamine D3Receptors GABA-ARo 15-4513 (PubChem CID: 5081)GABA(A)receptor3. Good healthProtein Subunits030104 developmental biologyEndocrinologynervous systemGene Expression Regulation030220 oncology & carcinogenesisGABAergicNucleus accumbensSB 277011A (PubChem CID: 75358288)
researchProduct

Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine‐N‐oxide

2018

Aims Trimethylamine-N-oxide (TMAO) is a novel cardiovascular risk marker. We explored the association of commonly used cardiovascular medications with TMAO levels in patients and validated the identified associations in mice. Methods Detailed history of drug treatment was recorded in 300 patients with cardiovascular disease without diabetes in an observational, cross-sectional study. Animal study was performed in CD1 mice. Results Median plasma TMAO (interquartile range) level was 2.144 (1.570-3.104) μmol l-1 . Among nine cardiovascular drug groups, the use of loop diuretics (0.510 ± 0.296 in users vs. 0.336 ± 0.272 in nonusers, P = 0.008) and mineralocorticoid receptor antagonists (0.482 ±…

0301 basic medicineMalemedicine.medical_specialtyOrganic anion transporter 1medicine.drug_classTrimethylamine N-oxide030204 cardiovascular system & hematologyKidneyExcretion03 medical and health scienceschemistry.chemical_compoundMethylaminesMice0302 clinical medicineSodium Potassium Chloride Symporter InhibitorsInternal medicineBlood plasmamedicineAnimalsHumansPharmacology (medical)AgedPharmacologybiologyChemistryArea under the curveFurosemideCardiovascular AgentsHeartOriginal ArticlesLoop diureticMiddle AgedProbenecid030104 developmental biologyEndocrinologyCross-Sectional StudiesLiverCardiovascular Diseasesbiology.proteinFemaleBiomarkersmedicine.drug
researchProduct

Viscosity-mediated negative food effect on oral absorption of poorly-permeable drugs with an absorption window in the proximal intestine: In vitro ex…

2014

Concomitant food intake can diminish oral absorption of drugs with limited permeability and an absorption window in the proximal intestine, due to viscosity-mediated decrease in dosage form disintegration time and drug dissolution rate. Three poorly-permeable drugs (atenolol, metformin hydrochloride, and furosemide) exhibiting negative food effect, and one highly-soluble and highly-permeable (metoprolol tartrate), serving as a negative control, were selected for the study. In vitro and in silico tools were used to evaluate the influence of media viscosity on drug bioperformance under fasted and fed conditions. The obtained results demonstrated that increased medium viscosity in the presence…

Absorption (pharmacology)DrugMetoprolol Tartratemedia_common.quotation_subjectPharmaceutical ScienceAdministration OralPharmaceutical formulationPharmacologyDosage formPermeabilityFood-Drug InteractionsPharmacokineticsPoorly-permeable drugsFurosemideHumansDissolution testingSolubilityDisintegrationmedia_commonChromatographyChemistryViscosityReproducibility of ResultsHydrogen-Ion ConcentrationFood effectMetforminAtenololIntestinal AbsorptionSolubilityFoodDissolutionAbsorption simulationEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Development and Characterization of an Amorphous Solid Dispersion of Furosemide in the Form of a Sublingual Bioadhesive Film to Enhance Bioavailabili…

2017

Administered by an oral route, Furosemide (FUR), a diuretic used in several edematous states and hypertension, presents bioavailability problems, reported as a consequence of an erratic gastrointestinal absorption due to various existing polymorphic forms and low and pH-dependent solubility. A mucoadhesive sublingual fast-dissolving FUR based film has been developed and evaluated in order to optimize the bioavailability of FUR by increasing solubility and guaranteeing a good dissolution reproducibility. The Differential Scanning Calorimetry (DSC) analyses confirmed that the film prepared using the solvent casting method entrapped FUR in the amorphous state. As a solid dispersion, FUR increa…

Absorption (pharmacology)medicine.medical_specialtymucoadhesive filmMaterials scienceBioadhesivePharmaceutical Sciencelcsh:RS1-44102 engineering and technology030226 pharmacology & pharmacyArticleSublingual Absorptionlcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineDifferential scanning calorimetryamorphous solid dispersiontransmucosal deliverymedicineSolubilityDissolutionAmorphous solid dispersion; Furosemide bioavailability; Mucoadhesive film; Sublingual absorption; Transmucosal delivery;021001 nanoscience & nanotechnologyfurosemide bioavailabilityAmorphous solidSurgeryBioavailabilitysublingual absorptionChemical engineeringSettore CHIM/09 - Farmaceutico Tecnologico Applicativomucoadhesive film; sublingual absorption; amorphous solid dispersion; furosemide bioavailability; transmucosal delivery0210 nano-technologyPharmaceutics
researchProduct

Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.

2009

Summary Background  In patients with cirrhosis, ascites is defined as refractory when it cannot be mobilized or recurs early in standard diuretic therapy. Aim  To compare the safety and efficacy of intravenous high-dose furosemide + hypertonic saline solutions (HSS) with repeated paracentesis in patients with cirrhosis and refractory ascites. Patients and methods  Eighty-four subjects (59/25 M/F) with cirrhosis, mostly of viral aetiology, admitted for refractory ascites, were randomly assigned to receive furosemide (250–1000 mg/bid i.v.) plus HSS (150 mL H2O with NaCl 1.4–4.6% or 239–187 mEq/L) (60 patients, Group A) or to repeated paracentesis and a standard diuretic schedule (24 patients,…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosismedicine.medical_treatmentPilot ProjectsRefractoryFurosemideAscitesmedicineParacentesishypertonic saline solutionHumansParacentesisPharmacology (medical)DiureticsAgedAged 80 and overSaline Solution HypertonicRCT; hypertonic saline solution; ascitesHepatologymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGastroenterologyFurosemideAscitesMiddle Agedmedicine.diseaseHypertonic salineSurgeryTreatment OutcomeEffusionAnesthesiaFemaleDiureticmedicine.symptombusinessRCTmedicine.drugAlimentary pharmacologytherapeutics
researchProduct

Effect of ouabain and furosemide on erythrocyte sodium and phosphate transport.

1981

The effects of ouabain and furosemide on the unidirectional efflux of sodium and phosphate ions were studied in freshly drawn human red blood cells (RBCs). In the presence of physiologic concentrations of sodium and potassium the rate of sodium efflux was reduced by 74% due to ouabain sensitivity. Furosemide (1.0 mmol/l) reduced ouabain-insensitive sodium transport rate by a further 50%. Thus, 13% of total sodium efflux was inhibited by furosemide when ouabain was present. In the absence of ouabain, however, furosemide inhibited 31% of total sodium transport, indicating that it also affected ouabain-sensitive sodium efflux. Phosphate transfer of RBCs was almost 1.0 mmol/l RBCs per hour. Ery…

AdultMaleCell Membrane PermeabilityErythrocytesPotassiumSodiumchemistry.chemical_elementBiological Transport ActiveOuabainIon ChannelsPhosphateschemistry.chemical_compoundHydrolysisFurosemidemedicineHumansPharmacology (medical)OuabainPharmacologyChromatographyChemistrySodiumFurosemidePhosphateBiochemistryPotassiumEffluxSodium-Potassium-Exchanging ATPaseAdenosine triphosphatemedicine.drugClinical pharmacology and therapeutics
researchProduct

Interaction of atenolol with furosemide and calcium and aluminum salts

1981

Six healthy subjects were treated with 100 mg atenolol. After a therapy-free interval of 4 wk the same subjects received the same dose of atenolol with furosemide, 40 mg, with calcium (as the lactate gluconate and carbonate), 500 mg, or with aluminum hydroxide, 5.6 gm. Atenolol alone and in combination was administered first as a single oral dose; a long-term 6-day treatment began 48 hr later. Addition of furosemide did not influence atenolol kinetics, but aluminum hydroxide led to an insignificant reduction (P greater than 0.05) of mean peak plasma levels of about 20% and of the area under the plasma concentration-time curve (AUC -infinity) from 5818 to 4353 ng ml-1 hr (P greater than 0.05…

AdultMaleTachycardiamedicine.medical_specialtyPhysical Exertionchemistry.chemical_elementBlood PressureCalciumPharmacologyPropanolaminesFurosemideHeart RateInternal medicinemedicineHumansDrug InteractionsPharmacology (medical)PharmacologyHealthy subjectsFurosemideAluminum saltsMiddle AgedAtenololKineticsPeak plasmaEndocrinologyBlood pressureAtenololchemistryHypertensionCalciumFemalemedicine.symptomAluminumcirculatory and respiratory physiologymedicine.drugClinical Pharmacology and Therapeutics
researchProduct

Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure

2000

Thirty patients aged 65-85 years, with refractory New York Heart Association (NYHA) class IV congestive heart failure (CHF) were treated with an intravenous infusion of furosemide (250-2000 mg/d) and small-volume hypertonic saline solution (150 mL of 1.4-4.6% NaCl) twice a day for 6 to 12 days. A daily fluid oral intake of 1000 mL and previous cardiac therapy were maintained. Clinical signs and symptoms of CHF, such as dyspnea, edema and weakness, improved, as did severity of illness as defined by NYHA class. The infusion was well tolerated. After a 12-month follow-up, 24 patients (80%) were alive and in the NYHA class assigned on discharge from the hospital. This therapeutic combination is…

Aged 80 and overHeart FailureMaleSaline Solution HypertonicAged; Aged 80 and over; Diuretics; Female; Furosemide; Heart Failure; Humans; Infusions Intravenous; Italy; Male; Saline Solution Hypertonic; Statistics Nonparametric; Survival RateStatistics NonparametricSurvival RateItalyFurosemideDiureticHumansFemaleInfusions IntravenouDiureticsInfusions IntravenousHumanAged
researchProduct

Pharmacological heterogeneity of γ-aminobutyric acid receptors during development suggests distinct classes of rat cerebellar granule cells in situ

2001

The gamma-aminobutyric acid receptor (GABA(A)R) represents a ligand-gated Cl(-)-channel assembling as heteropentamere from 19 known subunits. Cerebellar granule cells contain a unique subset, namely the alpha1-, alpha6-, beta2-, gamma2- and delta-subunits. We studied their GABAergic pharmacology in situ using whole-cell patch-clamp recordings in brain slices and a modified Y-tube application system. The distribution of the EC50s for GABA in young (P8-P14) and medium aged animals (P15-P28) could be fitted with the sum of two Gaussian distributions with means of 60 and 185 microM and 27 and 214 microM, respectively. In older animals (P29-P48) the observed homogeneous range of sensitivities fi…

Agingmedicine.medical_specialtyCerebellumPatch-Clamp TechniquesLoreclezoleConvulsantsIn Vitro TechniquesBiologyBicucullineInhibitory postsynaptic potentialAminobutyric acidMembrane PotentialsGABA AntagonistsRats Sprague-DawleyCellular and Molecular Neurosciencechemistry.chemical_compoundFurosemideCerebellumInternal medicineDMCMmedicineAnimalsDiureticsGABA ModulatorsReceptorPharmacologyDiazepamLong-term potentiationReceptors GABA-ARatsElectrophysiologymedicine.anatomical_structureEndocrinologychemistryGABAergicAlgorithmsCarbolinesmedicine.drugNeuropharmacology
researchProduct

803 Effects of high dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus, in re…

2003

Bolus (medicine)Hypertonic Saline SolutionSmall volumebusiness.industryAnesthesiaHeart failuremedicineFurosemideCardiology and Cardiovascular Medicinemedicine.diseasebusinessmedicine.drugEuropean Journal of Heart Failure Supplements
researchProduct